Deciphera Pharmaceuticals (DCPH)
In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on Deciphera Pharmaceuticals, with a price target of $21.00. The company’s shares closed last Friday at $16.51.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
Currently, the analyst consensus on Deciphera Pharmaceuticals is a Hold with an average price target of $13.83, which is a -18.6% downside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $23.00 price target.
Myriad Genetics (MYGN)
SVB Securities analyst Puneet Souda maintained a Hold rating on Myriad Genetics today and set a price target of $30.00. The company’s shares closed last Friday at $27.46.
According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Myriad Genetics with a $26.00 average price target, a -4.0% downside from current levels. In a report released today, Cowen & Co. also maintained a Hold rating on the stock with a $32.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DCPH:
- Analysts’ Opinions Are Mixed on These Industrial Goods Stocks: Lyft (LYFT) and Tupperware (TUP)
- First Industrial Realty Trust Declares Common Stock Dividends
- Stock Market Today – Friday, Aug 05: What You Need to Know
- Western Digital (WDC) Received its Third Buy in a Row
- Werner Enterprises to Participate in Two Virtual Investment Conferences